17,700 Shares in Supernus Pharmaceuticals, Inc. $SUPN Bought by Canada Pension Plan Investment Board

Canada Pension Plan Investment Board acquired a new stake in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 17,700 shares of the specialty pharmaceutical company’s stock, valued at approximately $823,000.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. BlackRock Inc. bought a new position in Supernus Pharmaceuticals in the second quarter worth about $434,871,000. Rubric Capital Management LP acquired a new stake in Supernus Pharmaceuticals in the second quarter worth about $21,908,000. Assenagon Asset Management S.A. acquired a new stake in Supernus Pharmaceuticals in the 1st quarter worth approximately $27,428,000. Woodline Partners LP lifted its stake in shares of Supernus Pharmaceuticals by 63.5% during the third quarter. Woodline Partners LP now owns 1,263,811 shares of the specialty pharmaceutical company’s stock worth $60,398,000 after buying an additional 490,835 shares during the period. Finally, Rice Hall James & Associates LLC acquired a new stake in Supernus Pharmaceuticals during the 2nd quarter worth about $22,800,000.

Supernus Pharmaceuticals Price Performance

Shares of SUPN stock opened at $43.74 on Wednesday. Supernus Pharmaceuticals, Inc. has a 1-year low of $42.45 and a 1-year high of $59.68. The firm has a market cap of $2.54 billion, a PE ratio of -22.78, a price-to-earnings-growth ratio of 0.82 and a beta of 0.56. The company has a 50-day moving average of $46.79 and a two-hundred day moving average of $48.54.

Supernus Pharmaceuticals (NASDAQ:SUPN) last released its quarterly earnings results on Monday, August 3rd. The specialty pharmaceutical company reported ($1.01) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.42 by ($1.43). Supernus Pharmaceuticals had a negative net margin of 13.23% and a positive return on equity of 11.13%. The company had revenue of $219.06 million during the quarter, compared to analysts’ expectations of $205.31 million. During the same period last year, the firm posted $0.40 earnings per share. Supernus Pharmaceuticals’s revenue was up 32.4% on a year-over-year basis. Sell-side analysts anticipate that Supernus Pharmaceuticals, Inc. will post 1.97 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

SUPN has been the topic of several recent research reports. Zacks Research raised shares of Supernus Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Thursday, August 6th. Cantor Fitzgerald lifted their price target on shares of Supernus Pharmaceuticals from $63.00 to $67.00 and gave the company an “overweight” rating in a research note on Thursday, July 9th. Wall Street Zen cut Supernus Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Saturday, August 8th. Finally, Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Supernus Pharmaceuticals in a research note on Wednesday, June 24th. One research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $62.83.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, headquartered in Rockville, Maryland, is a specialty pharmaceutical company dedicated to developing and commercializing central nervous system (CNS) therapies. Since its founding in 2003, Supernus has focused on advancing treatments for neurological disorders, with an emphasis on improving patient quality of life through innovative dosage forms and sustained‐release formulations.

The company’s marketed portfolio includes Trokendi XR and Oxtellar XR, extended‐release antiepileptic medications designed to maintain stable drug levels for seizure control, as well as Qelbree (viloxazine extended‐release capsules), approved for the treatment of attention‐deficit/hyperactivity disorder (ADHD) in pediatric and adult patients.